Suzanne Munck af Rosenschold
One of the nation’s leading authorities on the intersection of antitrust and intellectual property law.
A former federal enforcer, Suzanne advises U.S. and global companies in a wide variety of industries, including pharmaceuticals, healthcare, technology, industrial products and consumer goods. She focuses on U.S. and cross-border M&A, federal and state civil conduct investigations and all forms of compliance matters.
Prior to joining Davis Polk, Suzanne was for many years both Chief Counsel for Intellectual Property and Deputy Director of the Office of Policy Planning for the U.S. Federal Trade Commission. During her time at the FTC, Suzanne testified before the U.S. Senate on behalf of the agency and received awards for “outstanding work at the intersection of antitrust and intellectual property,” her healthcare and technology enforcement expertise and her policy work, including her leadership of the FTC’s 6(b) study of Patent Assertion Entities.
Suzanne is currently Vice Chair of the ABA Antitrust Section’s Pricing and Conduct subcommittee and Co-Chair of the Washington D.C. chapter of ChIPs.
Experience
- McKesson on its $850 million acquisition of a controlling interest in PRISM Vision
- REV Group on its $9 billion merger with Terex
- JetBlue on its strategic collaboration with United to launch BlueSky
- Endo, Inc. on its $6.7 billion merger with Mallinckrodt plc
- Obtained FTC approval of Novo Nordisk’s acquisition of certain Catalent sites from Novo Holdings
- Arcadium Lithium on its $6.7 billion acquisition by Rio Tinto
- Endo, Inc. on its $6.7 billion merger with Mallinckrodt plc
- Exxon Mobil on its $4.9 billion acquisition of Denbury
- Livent on its $10.6 billion merger of equals with Allkem
- Dufry on its combination with Autogrill
- UBS on its acquisition of Credit Suisse
- Chase Corporation on its $1.3 billion acquisition by KKR
- Relo Group on its combination of BGRS and SIRVA
- Republic Services on its $2.2 billion acquisition of US Ecology
- Rentokil Initial on its $6.7 billion acquisition of Terminix Global Holdings
- Obtained FTC clearance of Clarivate’s $5.3 billion acquisition of ProQuest
- Obtained DOJ clearance of IHS Markit’s:
- $44 billion all-stock merger with S&P Global
- Sale of OPIS business to News Corp
- Sale of Base Chemicals business to News Corp
- Gilead Sciences, Inc.’s:
- $21 billion acquisition of Immunomedics, Inc.
- $405 million acquisition of MiroBio
- Antitrust advice to AI company
- Several companies in civil conduct and 6(b) investigations by U.S. antitrust agencies and state attorneys general.
- DOJ issuance of a healthcare-related business review letter
Insights
News
Recognition
Federal Trade Commission – Paul Rand Dixon Award
Federal Trade Commission – Janet D. Steiger Award, four-time recipient
Education
- cum laude
- Editor, Minnesota Law Review
Prior experience
- Federal Trade Commission, 2007-2020
- Deputy Director, Office of Policy Planning, 2013-2020
- Chief Counsel for Intellectual Property, 2011-2020
- Attorney, Bureau of Competition and Office of Policy Planning, 2007-2011
- Senior Associate and Associate, Howrey, 2004-2007
- Associate, Sheppard Mullin Richter & Hampton, 2001-2004
Qualifications and admissions
- District of Columbia
- State of California